☰

Taylor H. Schreiber, Ph.D. - Publications

Affiliations: 
2010 University of Miami, Coral Gables, FL 
Area:
Oncology, Immunology
Tree Info Similar researchers PubMed Report error

57 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Wang C, Lai AY, Baiu DC, Smith KA, Odorico JS, Wilson K, Schreiber T, de Silva S, Gumperz JE. Analysis of Butyrophilin-Mediated Activation of γδ T Cells from Human Spleen. Journal of Immunology (Baltimore, Md. : 1950). PMID 37991420 DOI: 10.4049/jimmunol.2300588  0.432
2023 Shuptrine CW, Perez VM, Selitsky SR, Schreiber TH, Fromm G. Shining a LIGHT on myeloid cell targeted immunotherapy. European Journal of Cancer (Oxford, England : 1990). 187: 147-160. PMID 37167762 DOI: 10.1016/j.ejca.2023.03.040  0.339
2022 Lai AY, Patel A, Brewer F, Evans K, Johannes K, González LE, Yoo KJ, Fromm G, Wilson K, Schreiber TH, de Silva S. Cutting Edge: Bispecific γδ T Cell Engager Containing Heterodimeric BTN2A1 and BTN3A1 Promotes Targeted Activation of Vγ9Vδ2 T Cells in the Presence of Costimulation by CD28 or NKG2D. Journal of Immunology (Baltimore, Md. : 1950). PMID 36096643 DOI: 10.4049/jimmunol.2200185  0.694
2022 Yoo KJ, Johannes K, González LE, Patel A, Shuptrine CW, Opheim Z, Lenz K, Campbell K, Nguyen TA, Miriyala J, Smith C, McGuire A, Tsai YH, Rangwala F, de Silva S, ... Schreiber TH, et al. LIGHT (TNFSF14) Costimulation Enhances Myeloid Cell Activation and Antitumor Immunity in the Setting of PD-1/PD-L1 and TIGIT Checkpoint Blockade. Journal of Immunology (Baltimore, Md. : 1950). PMID 35817517 DOI: 10.4049/jimmunol.2101175  0.622
2019 de Silva S, Fromm G, Shuptrine CW, Johannes K, Patel A, Yoo KJ, Huang K, Schreiber TH. CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity. Cancer Immunology Research. PMID 31852716 DOI: 10.1158/2326-6066.Cir-19-0493  0.565
2019 Schreiber TH, Fromm G, Silva SD, Patel A, Johannes K, Yoo KJ, Huang K. Abstract 2271: Development and characterization of SL-115154 (CSF1R-Fc-CD40L) for cancer immunotherapy Cancer Research. 79: 2271-2271. DOI: 10.1158/1538-7445.Sabcs18-2271  0.564
2018 Fromm G, de Silva S, Johannes K, Patel A, Hornblower JC, Schreiber TH. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy. Journal For Immunotherapy of Cancer. 6: 149. PMID 30563566 DOI: 10.1186/S40425-018-0454-3  0.388
2018 Triplett TA, Garrison KC, Marshall N, Donkor M, Blazeck J, Lamb C, Qerqez A, Dekker JD, Tanno Y, Lu WC, Karamitros CS, Ford K, Tan B, Zhang XM, McGovern K, ... ... Schreiber TH, et al. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nature Biotechnology. PMID 30010674 DOI: 10.1038/Nbt.4180  0.47
2018 Fromm G, Silva Sd, Johannes K, Patel A, Hornblower JC, Schreiber TH. Abstract 5567: Agonist redirected checkpoint (ARC), SIRPα-Fc-CD40L, for cancer immunotherapy Cancer Research. 78: 5567-5567. DOI: 10.1158/1538-7445.Am2018-5567  0.549
2018 Fromm G, Silva Sd, Johannes K, Patel A, Hornblower J, Schreiber TH. Abstract 5564: Agonist redirected checkpoint, VSIG8-Fc-OX40L, for cancer immunotherapy Cancer Research. 78: 5564-5564. DOI: 10.1158/1538-7445.Am2018-5564  0.523
2018 Fromm G, Silva Sd, Johannes K, Patel A, Hornblower JC, Schreiber TH. Abstract 5559: Agonist-redirected checkpoint (ARC), TIM3-Fc-OX40L, for cancer immunotherapy Cancer Research. 78: 5559-5559. DOI: 10.1158/1538-7445.Am2018-5559  0.567
2017 Madireddi S, Eun SY, Mehta AK, Birta A, Zajonc DM, Niki T, Hirashima M, Podack ER, Schreiber TH, Croft M. Regulatory T Cell-Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9. Journal of Immunology (Baltimore, Md. : 1950). PMID 28877989 DOI: 10.4049/Jimmunol.1700575  0.696
2017 Garcia-Soto AE, Schreiber T, Strbo N, Ganjei-Azar P, Miao F, Koru-Sengul T, Simpkins F, Nieves-Neira W, Lucci J, Podack ER. Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors. Gynecologic Oncology. PMID 28392126 DOI: 10.1016/J.Ygyno.2017.03.512  0.599
2017 Steinberg GD, Shore ND, Karsh LI, Bailen JL, Bivalacqua TJ, Chamie K, Cochran JS, David R, Grubb RL, Harb WA, Holzbeierlein JM, Kamat AM, Trabulsi EJ, Walsh WV, Williams MB, ... ... Schreiber TH, et al. Immune response results of vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase II trial in patients with non-muscle invasive bladder cancer (NMIBC). Journal of Clinical Oncology. 35: 319-319. DOI: 10.1200/Jco.2017.35.6_Suppl.319  0.503
2017 Xu X, Gonzalez LE, Fromm GJ, Silva Sd, Giffin L, Rose J, Schreiber TH. Abstract 605: Potency of Gp96-Ig/Fc-OX40L cell-based combination vaccine in cancer immunotherapy Cancer Research. 77: 605-605. DOI: 10.1158/1538-7445.Am2017-605  0.594
2017 Silva Sd, Fromm G, Mukhopadhyay A, Campbell J, Pierce R, Schreiber T. Abstract 5617: Combined intratumoral electroporation and allogeneic vaccination of Gp96-Ig/Fc-OX40L stimulates CD8 T cell cross-priming to tumor specific neoantigens and enhanced anti-tumor response Cancer Research. 77: 5617-5617. DOI: 10.1158/1538-7445.Am2017-5617  0.585
2016 Fromm G, de Silva S, Giffin L, Xu X, Rose J, Schreiber TH. Gp96-Ig/costimulator (OX40L, ICOSL or 4-1BBL) combination vaccine improves T-cell priming and enhances immunity, memory and tumor elimination. Cancer Immunology Research. PMID 27364122 DOI: 10.1158/2326-6066.Cir-15-0228  0.559
2016 Morgensztern D, Harb WA, Schalper KA, Price ML, Early B, Schreiber TH. Broadening response rates to PD-1 therapy in advanced lung adenocarcinoma: Viagenpumatucel-l (HS-110) in combination with nivolumab in the ongoing DURGA trial. Journal of Clinical Oncology. 34: TPS9102-TPS9102. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps9102  0.539
2016 Silva Sd, Fromm G, Haque J, Campbell JS, Pierce RH, Schreiber TH. Abstract 567:In vivointra-tumoral electroporation of Gp96-Ig/Fc-OX40L stimulates CD8+ T cell cross-priming to tumor specific neoantigens Cancer Research. 76: 567-567. DOI: 10.1158/1538-7445.Am2016-567  0.586
2016 Fromm GJ, Silva Sd, Giffin L, Rose J, Goyal A, Schreiber TH. Abstract 2353: Combination immunotherapy: T-cell costimulation (OX40L, TL1A, 4-1BBL and ICOSL) secreted locally by Gp96-Ig vaccines, elicits robust antigen-specific, memory T cell responses and tumor elimination Cancer Research. 76: 2353-2353. DOI: 10.1158/1538-7445.Am2016-2353  0.58
2016 Schreiber TH, Fromm G, Xu X, Yusko E, Early B, Price M. Abstract 1405: Vesigenurtacel-L stimulates tumor infiltration of unique polyclonal T cell clones in non-muscle invasive bladder cancer patients Cancer Research. 76: 1405-1405. DOI: 10.1158/1538-7445.Am2016-1405  0.55
2015 Dranitsaris G, Cohen RB, Acton G, Keltner L, Price M, Amir E, Podack ER, Schreiber TH. Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents. Journal of Immunotherapy (Hagerstown, Md. : 1997). 38: 259-66. PMID 26261889 DOI: 10.1097/Cji.0000000000000089  0.576
2015 Hatfield SM, Kjaergaard J, Lukashev D, Schreiber TH, Belikoff B, Abbott R, Sethumadhavan S, Philbrook P, Ko K, Cannici R, Thayer M, Rodig S, Kutok JL, Jackson EK, Karger B, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Science Translational Medicine. 7: 277ra30. PMID 25739764 DOI: 10.1126/Scitranslmed.Aaa1260  0.677
2015 Cohen RB, Morgensztern D, Walsh WV, Bazhenova L, Melnyk AM, Beck JT, Nemunaitis JJ, Schreiber TH, Price ML. First interim exploratory analysis of immune response in patients with advanced non-small cell lung cancer receiving viagenpumatucel-l (HS-110) in combination with low-dose cyclophosphamide in an ongoing phase II trial. Journal of Clinical Oncology. 33: 3077-3077. DOI: 10.1200/Jco.2015.33.15_Suppl.3077  0.513
2015 Steinberg G, Shore N, Karsh L, Bailen J, Woods M, Schreiber T, Price M. Phase I study of patients with non-muscle invasive bladder cancer (NMIBC) treated with vesigenurtacel-L (HS-410) after Bacillus Calmette-Guérin (BCG) Journal For Immunotherapy of Cancer. 3: P447. DOI: 10.1186/2051-1426-3-S2-P447  0.39
2015 Fromm G, Rose J, Desilva S, Schreiber T. Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 costimulation for combination immunotherapy Journal For Immunotherapy of Cancer. 3: P371. DOI: 10.1186/2051-1426-3-S2-P371  0.581
2015 Garcia-Soto AE, Koru-Sengul T, Miao F, Schreiber T, Nieves-Neira W, Podack E. Abstract A24: Cancer-testis antigen expression is shared among gynecological tumors Cancer Immunology Research. 3. DOI: 10.1158/2326-6074.Tumimm14-A24  0.597
2015 Fromm GJ, Schilling N, Schreiber TH. Abstract 5037: Immunotherapy meets epigenetics: GP96-Ig cellular vaccine genetic signature is modulated by the inhibition of histone modifications Cancer Research. 75: 5037-5037. DOI: 10.1158/1538-7445.Am2015-5037  0.446
2014 Hatfield SM, Kjaergaard J, Lukashev D, Belikoff B, Schreiber TH, Sethumadhavan S, Abbott R, Philbrook P, Thayer M, Shujia D, Rodig S, Kutok JL, Ren J, Ohta A, Podack ER, et al. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection. Journal of Molecular Medicine (Berlin, Germany). 92: 1283-92. PMID 25120128 DOI: 10.1007/S00109-014-1189-3  0.624
2014 Cohen RB, Nemunaitis J, Gabrail N, Bazhenova L, Schreiber TH, Price M. A Phase II study of Viagenpumatucel-l (HS-110) in combination with low-dose Cyclophosphamide versus physician's choice in patients with advanced non-small cell lung cancer Journal For Immunotherapy of Cancer. 2: P82. DOI: 10.1186/2051-1426-2-S3-P82  0.421
2014 Steinberg GD, Shore N, Karsh L, Bailen J, Woods M, Schoenberg M, Schreiber TH, Price M. A Phase I/II study of vesigenurtacel-l (hs-410) or placebo in combination with Bacillus Calmette-Guérin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC) Journal For Immunotherapy of Cancer. 2: P81. DOI: 10.1186/2051-1426-2-S3-P81  0.374
2014 Schreiber TH, Schilling N, Deyev V, Podack ER. Abstract 5029: Comparative combination cancer immunotherapy with vaccination, checkpoint inhibition and TNFRSF stimulation Cancer Research. 74: 5029-5029. DOI: 10.1158/1538-7445.Am2014-5029  0.73
2014 Deyev VV, Schilling N, Schreiber TH. Abstract 2811: Allogeneic cell cased vaccine development by shared antigen screening Cancer Research. 74: 2811-2811. DOI: 10.1158/1538-7445.Am2014-2811  0.463
2014 Schreiber TH. Heat-Shock Protein-Based Cancer Immunotherapy Current Cancer Research. 12: 37-56. DOI: 10.1007/978-1-4614-8809-5_3  0.343
2014 Zhang Y, Schreiber TH, Rosenblatt JD. The Role of B Cells in Shaping the Antitumor Immune Response Current Cancer Research. 12: 19-35. DOI: 10.1007/978-1-4614-8809-5_2  0.425
2013 Strbo N, Garcia-Soto A, Schreiber TH, Podack ER. Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases. Immunologic Research. 57: 311-25. PMID 24254084 DOI: 10.1007/S12026-013-8468-X  0.637
2013 Schreiber TH, Podack ER. Immunobiology of TNFSF15 and TNFRSF25. Immunologic Research. 57: 3-11. PMID 24242819 DOI: 10.1007/S12026-013-8465-0  0.696
2013 Khan SQ, Tsai MS, Schreiber TH, Wolf D, Deyev VV, Podack ER. Cloning, expression, and functional characterization of TL1A-Ig. Journal of Immunology (Baltimore, Md. : 1950). 190: 1540-50. PMID 23319737 DOI: 10.4049/Jimmunol.1201908  0.791
2013 Zhang Y, Eliav Y, Shin SU, Schreiber TH, Podack ER, Tadmor T, Rosenblatt JD. B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion. Cancer Immunology, Immunotherapy : Cii. 62: 87-99. PMID 22772949 DOI: 10.1007/S00262-012-1313-6  0.677
2013 Schreiber TH, Gonzalez L, Wolf D, Bodero M, Podack ER. Abstract A38: T cell costimulation by TNFRSF4, TNFRSF18, and TNFRSF25 in the context of vaccination. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-A38  0.79
2012 Schreiber TH, Wolf D, Bodero M, Gonzalez L, Podack ER. T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination. Journal of Immunology (Baltimore, Md. : 1950). 189: 3311-8. PMID 22956587 DOI: 10.4049/Jimmunol.1200597  0.78
2012 Schreiber TH, Wolf D, Bodero M, Podack E. Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. Oncoimmunology. 1: 642-648. PMID 22934256 DOI: 10.4161/Onci.20298  0.739
2012 Wolf D, Schreiber TH, Tryphonopoulos P, Li S, Tzakis AG, Ruiz P, Podack ER. Tregs expanded in vivo by TNFRSF25 agonists promote cardiac allograft survival. Transplantation. 94: 569-74. PMID 22902792 DOI: 10.1097/Tp.0B013E318264D3Ef  0.634
2012 J Reddy PB, Schreiber TH, Rajasagi NK, Suryawanshi A, Mulik S, Veiga-Parga T, Niki T, Hirashima M, Podack ER, Rouse BT. TNFRSF25 agonistic antibody and galectin-9 combination therapy controls herpes simplex virus-induced immunoinflammatory lesions. Journal of Virology. 86: 10606-20. PMID 22811539 DOI: 10.1128/Jvi.01391-12  0.669
2011 Schreiber TH, Wolf D, Podack ER. The role of TNFRSF25:TNFSF15 in disease… and health? Advances in Experimental Medicine and Biology. 691: 289-98. PMID 21153333 DOI: 10.1007/978-1-4419-6612-4_30  0.559
2011 Schreiber TH, Khan SQ, Podack ER. Response to Taraban, Ferdinand, and Al-Shamkhani Journal of Clinical Investigation. 121: 465. DOI: 10.1172/Jci46113  0.744
2011 Zhang Y, Tadmor T, Eliav Y, Schreiber TH, Podack ER, Levy R, Shin S, Rosenblatt JD. Abstract LB-164: B lymphocytes inhibit anti-tumor response in a murine EMT6 tumor model by facilitating expansion of T regulatory cells Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-164  0.68
2010 Schreiber TH, Wolf D, Tsai MS, Chirinos J, Deyev VV, Gonzalez L, Malek TR, Levy RB, Podack ER. Therapeutic Treg expansion in mice by TNFRSF25 prevents allergic lung inflammation. The Journal of Clinical Investigation. 120: 3629-40. PMID 20890040 DOI: 10.1172/Jci42933  0.783
2010 Schreiber TH, Raez L, Rosenblatt JD, Podack ER. Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Seminars in Immunology. 22: 105-12. PMID 20226686 DOI: 10.1016/J.Smim.2010.02.001  0.572
2009 Schreiber TH, Podack ER. A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas. British Journal of Cancer. 101: 381-6. PMID 19638986 DOI: 10.1038/Sj.Bjc.6605198  0.545
2009 Schreiber TH, Deyev VV, Rosenblatt JD, Podack ER. Tumor-induced suppression of CTL expansion and subjugation by gp96-Ig vaccination. Cancer Research. 69: 2026-33. PMID 19223534 DOI: 10.1158/0008-5472.Can-08-3706  0.669
2009 Bayer AL, Jones M, Chirinos J, de Armas L, Schreiber TH, Malek TR, Levy RB. Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCT. Blood. 113: 733-43. PMID 18832651 DOI: 10.1182/Blood-2008-08-173179  0.519
2008 Oizumi S, Deyev V, Yamazaki K, Schreiber T, Strbo N, Rosenblatt J, Podack ER. Surmounting tumor-induced immune suppression by frequent vaccination or immunization in the absence of B cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 31: 394-401. PMID 18391756 DOI: 10.1097/Cji.0B013E31816Bc74D  0.688
2008 Bayer A, Jones M, Urbieta M, Chirinos J, Schreiber T, Armas L, Thomas M, Levy R. 44: The CD4+CD25+Foxp3+ Compartment Following Conditioning and Transplant: Host Treg Cells Expand and Comprise the Predominant Component for Several Months During Reconstitution post-HCT Biology of Blood and Marrow Transplantation. 14: 18-19. DOI: 10.1016/j.bbmt.2007.12.052  0.319
2007 Schreiber TH. The use of FoxP3 as a biomarker and prognostic factor for malignant human tumors. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 1931-4. PMID 17932340 DOI: 10.1158/1055-9965.Epi-07-0396  0.49
2007 Schreiber TH, Shinder V, Cain DW, Alon R, Sackstein R. Shear flow-dependent integration of apical and subendothelial chemokines in T-cell transmigration: implications for locomotion and the multistep paradigm. Blood. 109: 1381-6. PMID 17038526 DOI: 10.1182/Blood-2006-07-032995  0.379
2007 Bayer AL, Jones M, Urbieta M, Chirinos J, Schreiber T, De Armas L, Malek TR, Levy RB. Surviving Host CD4+CD25+Foxp3+ Cells Following Ablative Conditioning Expand and Comprise the Major Component of the Treg Compartment during the Lymphoid Reconstitution Period Following HCT. Blood. 110: 65-65. DOI: 10.1182/Blood.V110.11.65.65  0.52
Show low-probability matches.